You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

BREVIBLOC Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Brevibloc patents expire, and what generic alternatives are available?

Brevibloc is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in BREVIBLOC is esmolol hydrochloride. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Brevibloc

A generic version of BREVIBLOC was approved as esmolol hydrochloride by HIKMA on August 10th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BREVIBLOC?
  • What are the global sales for BREVIBLOC?
  • What is Average Wholesale Price for BREVIBLOC?
Drug patent expirations by year for BREVIBLOC
Drug Prices for BREVIBLOC

See drug prices for BREVIBLOC

Recent Clinical Trials for BREVIBLOC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Zagazig UniversityPhase 2
Cristália Produtos Químicos Farmacêuticos Ltda.Phase 4
University Hospital Bispebjerg and FrederiksbergPhase 4

See all BREVIBLOC clinical trials

Pharmacology for BREVIBLOC

US Patents and Regulatory Information for BREVIBLOC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-003 Aug 15, 1988 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-006 Feb 25, 2003 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-004 Feb 16, 2001 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BREVIBLOC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-003 Aug 15, 1988 ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-006 Feb 25, 2003 ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-006 Feb 25, 2003 ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-006 Feb 25, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BREVIBLOC

See the table below for patents covering BREVIBLOC around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0053435 COMPOUNDS SUITABLE FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS ⤷  Sign Up
Egypt 16108 METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS ⤷  Sign Up
Japan H0720861 ⤷  Sign Up
Poland 357387 ⤷  Sign Up
China 1455669 ⤷  Sign Up
Denmark 164660 ⤷  Sign Up
Denmark 335082 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.